Panel urges FDA to reject Novartis gouty arthritis drug on safety concerns
This article was originally published in Scrip
Executive Summary
Although Novartis' Ilaris (canakinumab) was effective in treating gouty arthritis, the safety of the drug in that indication is questionable, a panel of advisers to the US FDA said, advising the agency at a 21 June public meeting to reject the medication's marketing application until more data are available.